... and my final question, could this new partership in anyway conflict with our (the Biocurex shareholders) belief that Abbott recognizes Recaf as being a premier univeral cancer marker? Keep in mind that Breast cancer results have shown a better that 95% accuracy rate for both specificity and sensitivity, and I happen to know for sure, that Abbott knows that!!!
News 
Market Data 
Discover 
